Summary.-An attempt has been made to develop tritiated derivatives of Synkavit (menadiol sodium diphosphate, MNDP) of high specific activity as a radioactive drug.
peutic agent.
In all, 214 patients with different sites and types of advanced and recurrent, inoperable, histologically verified malignant tumours including reticuloses have been treated with doses of at least 1 Ci of the various preparations. Among the 203 evaluable treated cases, some form of response was observed in 23 out of 151 (15 -2%) receiving the drug by intravenous injections and 13 out of 52 (25%) after intra-arterial injections. For the sites and types of malignant diseases which showed responses after either intravenous or intra-arterial administration among the 55 patients surviving at least 3 months after the first injection, some form of response was observed in 32 but only 5 of these showed either a " complete " or a " partial" response.
It is concluded that further investigation is desirable. It is suggested that clinical trials with randomization should be carried out for inoperable cases of carcinoma of the colon and of the pancreas.
As A METHOD of improving the treatment of patients with cancer, I thought it was important to try to develop radioactive drugs, i.e., compounds which are concentrated selectively in the viable malignant cells of tumours and carry incorporated radioactive atoms in sufficiently high specific activity to the right place, in order to produce the radiotherapeutic effect in situ, and without significant damage to normal tissues. The present work arose from studies of chemical radiosensitizers, which started in 1946 with Synkavit (Roche Products Ltd, menadiol sodium diphosphate, MNDP). We noticed that a few minutes after intravenous injection of doses of 100-150 mg of MNDP some patients experienced sensations or even local pain in the region of the tumour. Following up this unexpected finding, investigations showed that MNDP, or a major metabolite of it, concentrated to some extent selectively in the malignant cells of some experimental tumours in animals and certain human tumours.
For therapeutic applications, we have developed tritiated derivatives of MNDP -abbreviated T-MNDP-incorporating tritium, (3H) in very high specific activity. This is the work of a team in Cambridge, with the collaboration of the Radiochemical Centre, Amersham, Bucks., and Roche Products Ltd, Welwyn Garden City. It started in 1953 with the preparation of. derivatives of MNDP and some related compounds, labelled with 14C, 82Br, 1311 and finally tritium, with progressively increasing specific activity (Maxwell, 1954 (Maxwell, , 1955 Marrian and Maxwell, 1956a, b; Marrian, 1957; Horwitz et al. (1959) ; Andrews et al., 1962; Hodgson, 1968; Thomas, personal communication, 1970) . The various aspects of this investigation and published work on other radioactive drugs have been reviewed (Mitchell, 1965 (Mitchell, , 1967 (Mitchell, , 1970 (Mitchell, , 1971a .
Relevant properties of tritiurn and approximate clinical dosimetry
Tritium (3H) appears to be very suitable for incorporation into a radioactive drug. Its radiobiological action is localized in single cells or cell constituents. It is a pure beta ray emitter with very soft beta radiation which behaves biologically like a low LET radiation. The beta particles are completely absorbed in about 6 ,am in water and soft tissue of unit density. The mean energy of the beta particles is 5 73 ± 0 03 keV and the corresponding range in unit density tissue is approximately 0 9 rim. The radioactive half-life is 12-4 years but almost invariably the values of the biological half-life (BHL) observed for human tissues and tumours with the radioactive drugs T-MNDP have been very much less, often between 7 and 14 days for the main half-life, though sometimes less, and in sone cases greater for tumour than for normal tissues (Chipperfield, 1967a) . Values of the main half-life found for carcinoma of the rectum were 9 and 13 days; a value of 3-4 days was observed in a case of squamous carcinoma of the skin.
It is useful to introduce the concept of the Differential Absorption Ratio (DAR) defined as the ratio of the specific activity of the tumour or relevant normal tissue to the mean specific activity of the body as a whole. An important step in the investigation of the individual patient is the measurement of the specific activity of tumour tissue, and also at least one normal tissue, if possible. There are, of course, some cases where it is not practicable to carry out such procedures.
The most important quantitative relationship concerning the dosimetry is that for uniformly distributed tritium at a stationary concentration, 1 mCi per g of tissue delivers a dose rate of 293 rad per day (24 h).
As a first approximation, calculations of radiation dose based on the assumption of uniform distribution of the tritium in normal tissues and tumours have proved useful.
Assuming uniform distribution throughout the body, 1 Ci of tritium administered in a single injection to a 70 kg patient delivers a dose of 18-1 rad for a BHL of 3 days, 36-2 rad for BHL 6 days, 54-4 rad for BHL 9 days, 72-5 rad for BHL 12 days and 78-5 rad for BHL 13 days (Mitchell et al., 1963 (Chipperfield, 1967a) . It was found that in most cases a power law gave a good or even better fit for the dependence of specific activity upon time but with this method calculation of the dose delivered was more difficult (White, 1973) .
For doses calculated on the assumption of a uniform distribution of the tritium of T-MNDP in normal tissues and tumours, it appears that in most cases the clinical results are not inconsistent with experience of external radiotherapy, if the further assrumption is made that the RBE has the value of 15 in relation to 60Co gamma radiation. Such a value is probably not inconsistent with previous experimental findings (see e.g., Hall, Oliver and Bedford, 1967, and our own EM-autoradiographic studies, noting also the work of Cleaver, 1971.) .
However, the basis for these calculations can only be regarded as a crude first approximation. In general, in addition to macroscopic inhomogeneity there is inhomogeneity of the microscopic distribution of the tritium, which has been studied by morphometry and by autoradiography including EM-autoradiography, in addition to measurements of the specific activity of the tritium in macroscopic specimens. With regard to the human tumours studied (Chipperfield, 1 967a), the initial uptake observed in biopsy and surgical specimens taken 30 min after intravenous or intra-arterial injection was highest in cases of carcinoma of the gastrointestinal tract, with values of 22*1 ± 8-4 1Cli per g wet weight per Ci injected for TRK 219 and 27*4 i 2X2 ,uCi per g per Ci injected for TRA 119. In some of these tumours and their metastases there was abundant stroma which showed low uptake, so that the mean specific activity of the tumour cells may be considerably higher than the average value for the macroscopic specimen, e.g., in one case by a factor of 6 3. There is often wide variation among the tumour cells and in different parts of the tumour. Taking into account this distribution of activity, it is possible to calculate an approximate value of the nmean tumour cell dose, but difficult to estimate the minimum tumour cell dose, even though the uptake is limited to viable tumour cells. In a typical example of carcinoma of the colon, the specific activity of the gross specimen may be 20 ,uCi per g per Ci injected, so that allowing for stroma and necrotic areas by means of a factor of 3*5, the mean specific activity of the tumour cells would be 70 /tCi per g per Ci
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and for a single dose of 10 Ci injected 0 70 mCi per g; the corresponding initial mean tumour cell dose would be 205 rad per 24 h. For a typical value of the biological half-life of 10 days and mean life 14 4 days, the total mean cell dose delivered would be 2950, say of the order of 3000 rad. Assuming a value of the RBE of 1P5, the total mean tumour cell dose would be equivalent biologically to about 4500 rad of y radiation delivered continuously over about 14 days. Examples of calculations for the repeated small doses generally used in the treatment of individual patients will be discussed in considering the results.
From the point of view of detailed dosimetry, as a further extension of the ordinary (light microscopic) autoradiography (Mitchell et al., 1963) quantitative EM-autoradiographic studies have been carried out on tumour cells in sections from patients treated with T-MNDP. Significant concentration, often by factors of 3-5, was found in the nucleoli and nucleolus associated chromatin, mainly in the mid and late S and early G2 phases.
It is to be noted that the introduction of tritium as a hydrogen isotope into an organic molecule such as MNDP causes no change in its chemical structure or pharmacological properties. Almost certainly there is no significant isotope effect. Moreover, the properties of tritium and of T-MNDP and its metabolism are such that the handling of these preparations presents no serious difficulties in therapeutic applications. The health and safety precautions described (Mitchell, 1965) (Andrews et al., 1962 (Hodgson, 1968;  Thomas, personal communication, 1970 (Evans, 1966) .
With these radioactive drugs, one needs a high degree of radiopharmaceutical purity, as well as of radiochemical purity. Even nouw, the individual batches may differ in biological properties. For this reason every batch of T-MNDP is tested routinely on tissue cultures with autoradiography to be certain of a high degree of selective uptake in cells of a human tumour strain, Hep/2 (derived from a nasopharyngeal carcinoma) with negligible uptake into cells of normal origin, for which we now use mouse L cells. In earlier stages of the testing, other cells were included, viz., HeLa cells and normal cells of human amniotic epithelium and embryonic skin, and lung epithelium, as well as monkey kidney cells (Simon-Reuss, 1961; Dendy, 1969; Morley and Dendy, 1973) . A bad " batch shows uptake into the cells of normal origin. Quantitatively, ' good " batches show from 30 up to even 100 times the uptake into the tumour cells compared with that in the normal cells. These tests also provide a check for sterility. In addition, every batch has been tested to exclude acute toxicity-which has never been observed after intravenous injection in rabbits in doses corresponding to 11 Ci and 22 Ci/70 kg body weight. These rabbits have been kept for the rest of their life span for studies of possible late radiation effects.
Pre-clinical testing.-In this investigation, using the preparations of T-MNDP of very high specific activity, the chemical toxicity of MNDP is negligible (Mitchell, 1948 (Mitchell, , 1949 . In addition to the tissue culture studies, many experiments have been carried out on mice, rats and rabbits; these have been continued throughout the years and included haematological studies on the rabbits. Di Vita (1964, personal communication) showed that in mice for a single intraperitoneal injection of TRA 72, the LD 50/30 days was about 20 mCi/g body weight, but only 1 1 mCi/g for tritiated water, for which there is essentially uniform distribution of the radioactivity: a value of about 1 mCi/g had also been found for tritiated water by Brues, Stroud and Rietz (1952) . The results of our distribution studies with T-MNDP in rats wvith the Walker carcinosarcoma 256 were confirmed for mice with spontaneous mammary adenocarcinoma by Ganatraet al. (1969 in inorganic form in therapy. The value and limitations of approximate dosimetry for these two isotopes had been emphasized in many investigations, including our own (Phillips, 1954 (Phillips, , 1957 Phillips and Saunders, 1957; Phillips, Haybittle and Newberry, 1960; Mitchell, 1955 Mitchell, , 1971a . With T-MNDP, the estimated radiation doses proved to be a reliable starting point as a first approximation, which enabled us to make rapid progress. Partly because of this, and also because no other basis would have been acceptable, wre set out to include assessment of anti-tumnour action in the Exploratory Phase, corresponding to Phase I, of our trials. Further, the investigations which can be regarded as within the scope of clinical pharmacology as applied to a radioactive drug have continued throughout most of Phase II; also the quality of the radioactive drug has improved steadily over the years.
In Phase 1, we started the treatment of patients with advanced or refractory tumours" using intra-arterial (i.a.) injection, mainly with the Seldinger technique as developed by Dr D. McC. Gregg (1958) , and then used intravenous (i.v.) injections in patients with generalized metastases " (HorwNitz et al., 1959) . We noted that Gehan (1961) had shown that if a drug wAere effective in 20% of patients, or more, there wNould be a 950 chance of one or more successes in 14 consecutive cases. Wre found 5 responses which were estimated on the modest basis of reduction in size of the tumour, or of part of the tumour in the first 14 cases. Accordingly, w!e felt wre must continue the investigation and wre were encouraged by the relief of pain we observed in 5 of these patients.
From the beginning we started relevant investigations and first obtained evidence of uptake of T-MNDP in tumours after i.a. injection. Detailed studies of tritium uptake and distribution, half-lives and radiation doses, and excretion and metabolism have continued (Horwitz et al., 1959; Mitchell, 1961: Marrian et al., 1965; Chipperfield, 1967a, b; see also White, 1973 Gerner and Moore, 1973) including: (a) reduiction of the size of the tumour with less than a 5000 decrease in the maximum cross-sectional area, or (b) more than a 500o decrease in the maximum cross-sectional area of the tumour or of parts of the tumour, wzTith simultaneous progression of the disease elsewhere, or (c) significant improvement of general condition and increase in performance status (Karnofsky et al., 1951) or (d) useful relief of pain, if possible assessed in terms of reduction of the amounts of analgesic drugs required, or (e) relief of intractable pruritus, or more than one of these criteria.
Responses were required to persist for at least 4 weeks.
None. No significant clinical response. This includes: no change or stationary disease, and progression, defined as a measurable increase in the maximum cross-sectional area of the tumour greater than 250%, or appearance of new lesions, or definite worsening of the patient's general condition.
N.E. Non-evaluable treatments were studied, and classified as follows: Not evaluable because treatment was initiated prophylactically for poor prognosis as adjuvant therapy following, or in association with, radiation therapy or surgery, including potentially curative measures, or not curable by standard means, but no lesions were evaluable for measurement. Included were patients who were treated with radiation therapy and chemotherapy simultaneously or previously and in this case died within 1 month of the complications of the previous treatment.
RESULTS
The results of treatment of the 162 patients with the various preparations of T-MNDP administered by intravenous injection are sunmmarized in Table I cervical nodes after previous radiotherapy, 3 P.R., one of which was a case of carcinoma of the colon made operable and the other 2 of carcinoma of the pancreas, and 18 Inc.R., some of which were striking.
For intra-arterial administration, all 52 patients treated with doses of 1 Ci or more were evaluable. Table IV gives further details of the results of intra-arterial treatment with T-MNDP for the 18 patients with malignant diseases of sites and types which showed some responses. Among the 13 of these patients surviving at least 3 months after the first intra-arterial injection, there were 1 P.R., in a case of multiple metastases of malignant n elanoma on the leg, with freedom from any evidence of disease for 3 years 4 months, and 9 Inc.R.
For all the evaluable patients in the trial treated by both the intravenous and intra-arterial routes, there was some form of response in 36 out of 203 Moderately well-different iated adenocarcinoma. On phenobarbitone for some years. Striking uptake wNas observed in scan with 6-1311-iodo-MNDP. 'I'he total dose of 11-3 Ci of TRK 397 was given in 8 intravenous injections in 25 days. Body weight 57 kg. For 70 kg body weight, this is equivalent to 8 injections each 1P74 Ci, with total 13-9, say 14 Ci. Assuming a biological half-life (BHL) of 9 days and DAR = 5 for the tumour cells, the total mean dose delivered would be 3780 rad. With RBE _ 1-5, the equivalent total mean dose of _iCo gamma radiation to the tumour cells is about 5700 rad delivered in a time probably equivalent to an overall time of 38 days, corresponding to the time between the first and last injections plus the assumed biological mean life of 13 days. There were no serious blood count changes. The minimum values reached were wbc 3000 and platelets 129,000/cm3 at 29 days after the last injection.
A useful clinical response was obtained. Trhe palpable mass disappeared from 2 to 7 moniths after the start of the injections but greN again slowly. The condition was then regarded as operable and was treated surgically at 8 months after the first injection, with resection of splenic flexure with left kidney". The patient was alive and well 2 years after the resection. wNith occasional acini, some containing mucus. Striking uptake was observed in scans with 6-1311-iodo-MNDP. From measurements on a phantom model, the value of the macroscopic average DAR for uptake of 6-131I1 iodo-MNDP into the primary tumour mass was found to be 6-8 (say 7) (Mitchell, 1971a, p. 66 and Fig. 4) . The total dose of 13-6 Ci of TRK 219 was given in 6 intravenous injections in 15 days. Body wreight 54 kg.
For 70 kg, this would be equivalent to 6 injections each of 2-93 Ci, w\ith total 17-6 Ci.
Sodium citrate mixture was given orally during the treatment to try to increase the u]ptake into the tumour. Assuming BHL 6 days and DAR = 7 for the tumour, the total mean dose delivered would be 4450 rad. With RBE = 1-5, the equivalent total mean dose would be about 6700 rad, delivered in an effective time of about 24 days. There were no serious blood count changes. The minimum values reached were wbc 2900 and platelets 195,000/Cm3 at 23 days after the last injection.
The abdominal mass below the left costal margin became only just palpable or not palpable for at least 4 weeks and then slowly enlarged. At 2 months after the end of the first course of injections, a second course was given to a total dose of 8-4 Ci in 3 injections in 7 days. There was only slight improvement in general condition, with a little reduction in size of the mass. The patient died 4 months 15 days after the start of the first course of injections.
Case .No. 266 (Addenbrooke's Hospital No.
339607)
P.R. Female, 23 years. Proven metastases liver and coeliae axis lymph nodes, almost in certainly primary carcinoma in body of pancreas-inoperable at laparotomy; also hypercaleaemia with no radiological evidence of metastases in bones. Poorly differentiated adenocarcinoma. The total dose of 15-4 Ci was given in 7 intravenous injections in 16 days. Body weight 41-5 kg. For 70 kg, this would be equivalent to 7 injections each of 3-71 Ci, with total 26 Ci. During the injections, the patient w\as treated with prednisone 30 mg daily and also chloroquine sulphate 200 mg tablets twice daily (as a DNA repair inhibitor; Mitchell, 1973) ; this was continued for 4 weeks after the injections. Assuming BHL 6 days and DAR = 5 in the tumour cells, the total mean dose delivered would be 4690 rad. With RBE= 1-5 the equivalent total mean dose would be about 7000 rad, delivered in an effective time of about 25 days. There were no serious blood count changes. The minimum values reached wNere wbc 3500 and platelets 103,000/cm3 at 27 days after the last injection; the neutrophils showed toxic granulations.
There was a steady reduction in the size of the liver for at least 3 months and striking improvement of the general condition for at least 2 months. Then she deteriorated very slowly but finally died after about a week's illness with bronchopneumonia and pains in the back and legs, possibly due to spinal metastases, at 157 days after the first injection.
Case No. 13 (Addenbrooke's Hospital No.
162632)
P.R. Male, 60 years. Massive recurrence in abdomen and pulmonary metastases from seminoma arising in undeseended testicle, after surgery and large field radiotherapy, which resulted in a leueopenia reaching 1500 wbe/Cm3, and 2 blood transfusionls. A single intra-aortic injection of 3 Ci of TI was given. The catheter was inserted intraarterially by the Seldinger method, Nith the tip in the aorta below the branch to the left subelavian artery. Body weight 58 kg. The abdominal mass shrank rapidly and became only just palpable. The oedema of the legs disappeared. The patient no longer needed morphia for the pain and he could lie flat in comfort. At 33 days after the injection rapid deterioration occurred, almost certainly due to a haemorrhage into tumour. The Hb fell to 8-1 g/100 ml and rapidly over 14 days the total wbc fell to 400 and the platelets from 115,000 to 10,000/cIn3. A blood transfusion was given but the patient died 9 days later. Autopsy showed complete necrosis of the para-aortic mass, hypoplastic sternal marrow and sheets of seminoma cells in the liver, lung parenchyma and lymph nodes adjacent to the left bronchus. 70 kg, the total dose would be 48 Ci). Assuming BHL 6 days and DAR = 3, the total mean dose delivered would be about 5200 rad. WAith RBE = 1 5, the equivalent total mean dose would be about 7800 rad delivered in effective time about 43 days.
After being rather ill, though relieved by aspiration of the pleural effusion and a blood transfusion, she improved considerably in general condition, the palpable tumour masses became less tender and slightly smaller and the papilloedema decreased. She said that after the injections she felt like she did after the previous external radiotherapy.
The blood count shoNed serious changes at about 44 days after the first injection with minimum values Hb 7-3 g/100 ml, total wbc 1200, with lymphocytes 516 and platelet count 10,000/cm3; rapid recovery occurred within 2 weeks after blood transfusions.
There was striking subjective improvement with P.S. 80-90% for 10 weeks. She acquired a new-flat and new furniture and went away for a holiday. Then she deteriorated with increasing size of the tumour masses but with an essentially normal blood count. There was no response to a further single intravenous dose of 2-6 Ci of TRK 219. She died at 6 months 10 days after the first injection. Autopsy showed carcinomatosis.
The bone marrow appeared normal, the kidneys were congested and showed some scarred glomeruli. In these trials there has never been evidence of renal damage. It is important to note that experience of the treatment of carcinoma of the thyroid with large doses of radio-iodine, 1311, has shown that there is no evidence of long-term damage to the kidney (Pochin, 1969, personal communication) .
In one case (No. 52) of multiple metastases of malignant melanoma on the leg, intra-arterial therapy with TRA 119 reduced the tolerance of both skin and underlying bone to small field local radiotherapy; a normal dose of external 220 kVp x-rays resulted in a local radionecrosis, requiring surgical treatment and skin grafting.
Nausea is a not very common and never serious complication and has been experienced by some patients even after intravenous injections of 2-3 Ci; it is con-trolled almost invariably by oral perphenazine (Fentazin) 
Ancillary procedures
Many laboratory and clinical studies have been made to try to increase the selective uptake of T-MNDP into tumours. The most encouraging ancillary agent is prednisone, which appears to increase the alkaline phosphatase on the tumour cell surface in some cases; the effects on normal cells must be studied further. The possibilities of the use of phenobarbitone as an enzyme inducer should also be considered. Fasting appears to be of practical value (White, 1973) . In in vitro experiments with Ehrlich ascites tumour cells it had been found that lack of glucose in the medium increased the dephosphorylation of MNDP but not of ATP (Fisher, 1968, personal communication; see Mitchell, 1971a, p. 46 have some effect but it is doubtful whether this procedure is of sufficient practical value to justify its further study. Acetylcholine did not increase the uptake, as studied by scanning with 6-1311-iodo-MNDP but produced local pain in the region of the tumour. It must be noted that tolazoline (Priscol) was used as a vasodilator with many of the intra-arterial injections. Recently, interesting results have been obtained by the use of chloroquine as a DNA repair inhibitor to try to increase the effects of the radiation delivered by the radioactive drug, perhaps selectively in the tumour cells (Mitchell, 1973) .
We have made many attempts to select patients for treatment on the basis of measurements of the uptake of MNDP into the tumour, using the following investigations: It is suggested that Phase III should be started, with controlled clinical trials, with proper design and random allocation of patients-perhaps with chemotherapy in the control groups for the treatment of inoperable cases of carcinoma of the colon and of carcinoma of the pancreas.
Further studies of ancillary agents and procedures to improve the selection of patients appear to be necessary.
The possibilities of T-MNDP in the treatment of selected patients with advanced carcinoma of the rectum, breast and ovary and with advanced Hodgkin's disease and testicular seminoma have probably not been fully explored and appear to justify further investigation. Studies of rare tumours, such as primary hepatoma, should also be envisaged.
This work provides further evidence that tritium, when incorporated into a suitable compound, can produce therapeutic effects in patients with malignant diseases of certain sites and types. The scope and limitations of the effectiveness of T-MNDP as a radioactive drug appear to depend not only on the nature and properties of the carrier molecule, which are obviously of essential importance, but also on the biochemistry and pathological physiology of the tumour, especially on the blood supply and size of the tumour masses and the interrelationships of the tumour and the host.
